Biography:Irene Ghobrial

From HandWiki
Short description: American-Egyptian physician and academic
Irene Ghobrial
Born
Egypt
Alma materWayne State University
Cairo University
Scientific career
FieldsScience
Medicine
Oncology
Myeloma
MGUS[1]
InstitutionsMayo Clinic
Dana–Farber Cancer Institute
Harvard Medical School
Website{{{1}}}

Irene Ghobrial is an American-Egyptian physician who is a professor at the Dana–Farber Cancer Institute[2] and Harvard Medical School,[1][3] where her research investigates the progression of multiple myeloma. She is interested in why certain patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma develop B cell malignancies. She leads the Stand Up to Cancer multiple myeloma dream team.

Early life and education

Ghobrial was born in Egypt and studied medicine at Cairo University.[4] After graduating, she moved to Detroit, where she completed her specialist training at Wayne State University.[5][6] She has said that she experienced considerable challenges as an immigrant,[citation needed] but ultimately completed her internal training. In 2000, she moved to the Mayo Clinic, where she worked with Karen Hedin and Robert A. Kyle in hematology and oncology.[5]

Research and career

Ghobrial is an expert in multiple myeloma, cancer of the plasma cells. Myleoma is a rare condition that disproportionately impacts African Americans, often at a young age. Ghobrial studies how multiple myeloma use cell dissemination and cell metastasis, and looks to identify warning signs that will permit earlier treatment.[5][7] She believes that these treatments may begin as early as during smouldering myeloma,[8] a precancerous condition that occurs when the immune system is strong and the tumor burden is low.[9]

In 2011, Ghobrial was elected to the American Society for Clinical Investigation.[10] In 2018, she was awarded $10 million from Stand Up to Cancer to establish the Multiple Myeloma Dream Team, which looks to understand the precursors that indicate a risk of developing myeloma.[11] She leads the clinical trial PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population), which built a cohort to identify individuals with a high likelihood of developing multiple myeloma.[12][13] Her research uses mass spectrometry to screen for monoclonal gammopathies (abnormal proteins found in the blood), and revealed that 13% of her patient cohort had MGUS.[14] Her research demonstrated that Black individuals were considerably more likely to have MGUS than previously expected.[14]

Ghobrial worked with chemists at Massachusetts Institute of Technology to design nanoparticle-based strategies for targeted cancer therapies, which promotes the accumulation of drugs at tumor sites and reduces toxic side effects.[15][16]

In 2022, Ghobrial was awarded the William Dameshek Prize.[17]

Selected publications

Personal life

Ghobrial spends her spare time raising money for cancer charities. She has climbed Mount Kilimanjaro[18] and run a marathon[19] to raise money for leukaemia and lymphoma research.

References

  1. ↑ 1.0 1.1 {{Google Scholar id}} template missing ID and not present in Wikidata.
  2. ↑ {{{1}}}
  3. ↑ Irene Ghobrial publications from Europe PubMed Central
  4. ↑ Gatta, Frances (2023). "How my training helps me to address health disparities in multiple myeloma: Irene Ghobrial’s research on early detection of this type of bone-marrow cancer aims to improve patient outcomes, especially among African Americans" (in en). Nature. doi:10.1038/d41586-023-01587-9. PMID 37165230. 
  5. ↑ 5.0 5.1 5.2 "Irene Ghobrial, MD" (in en). American Association for Cancer Research. https://www.aacr.org/governance/irene-ghobrial/. 
  6. ↑ "Director, Clinical Investigator Research Program – Dana-Farber" (in en). http://physicianresources.dana-farber.org/participant/irene-ghobrial-md. 
  7. ↑ Manier, Salomon; Salem, Karma Z.; Liu, David; Ghobrial, Irene M. (2016). "Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 35: e400–406. doi:10.1200/EDBK_159010. ISSN 1548-8756. PMID 27249747. https://pubmed.ncbi.nlm.nih.gov/27249747/. 
  8. ↑ Figueiredo, PhD, Marta. "MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma" (in en-US). https://myelomaresearchnews.com/news/mmrf-partners-with-dana-farber-to-advance-research-in-smoldering-myeloma/. 
  9. ↑ "Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma" (in en). https://www.onclive.com/view/dr-ghobrial-on-future-efforts-to-prevent-the-development-of-multiple-myeloma. 
  10. ↑ "The American Society for Clinical Investigation" (in en-US). https://the-asci.org/contact.shtml. 
  11. ↑ Chen, Angus (2022-04-21). "Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early" (in en-US). https://www.statnews.com/2022/04/21/searching-for-early-detection-of-multiple-myeloma/. 
  12. ↑ Ghobrial, MD, Irene (2022-03-22). Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE). Dana-Farber Cancer Institute, Stand Up To Cancer. https://clinicaltrials.gov/ct2/show/NCT03689595. 
  13. ↑ "Smoldering Multiple Myeloma – A Unique New Approach – Dana-Farber" (in en). http://physicianresources.dana-farber.org/videos/smoldering-multiple-myeloma-a-unique-new-approach. 
  14. ↑ 14.0 14.1 El-Khoury, Habib; Lee, David J; Alberge, Jean-Baptiste; Redd, Robert; Cea-Curry, Christian J; Perry, Jacqueline; Barr, Hadley; Murphy, Ciara et al. (2022). "Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study" (in en). The Lancet Haematology 9 (5): e340–e349. doi:10.1016/S2352-3026(22)00069-2. ISSN 2352-3026. PMID 35344689. 
  15. ↑ Massachusetts Institute of Technology. "Using bottlebrush-shaped nanoparticles, researchers can identify and deliver synergistic combinations of cancer drugs" (in en). https://phys.org/news/2023-01-bottlebrush-shaped-nanoparticles-synergistic-combinations-cancer.html. 
  16. ↑ Detappe, Alexandre; Nguyen, Hung V.-T.; Jiang, Yivan; Agius, Michael P.; Wang, Wencong; Mathieu, Clelia; Su, Nang K.; Kristufek, Samantha L. et al. (2023). "Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma" (in en). Nature Nanotechnology 18 (2): 184–192. doi:10.1038/s41565-022-01310-1. ISSN 1748-3395. PMID 36702954. 
  17. ↑ "Dana-Farber professor receives William Dameshek Prize for multiple myeloma research" (in en). https://www.healio.com/news/hematology-oncology/20221210/danafarber-professor-receives-william-dameshek-prize-for-multiple-myeloma-research. 
  18. ↑ Torcivia, Rosalina. "Senior Leader Interview – Dr. Irene Ghobrial" (in en-us). https://info.westorg.org/blog/interview-irene-ghobrial. 
  19. ↑ GreifA (2016-06-20). "Cancer Researcher Runs Alaska Half Marathon to Raise Funds for Lifesaving Treatments" (in en). https://www.schoolandyouth.org/blog/cancer-researcher-runs-alaska-half-marathon-to-raise-funds-for-lifesaving-treatments. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Irene_Ghobrial&oldid=3440265"